Basics BioMarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc is on rare-disease therapies. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. IPO Date: August 1, 1999 Sector: Healthcare Industry: Biotech Market Cap: $10.26B Activated in VL: True Average Daily Range Avg Daily Range: $0.86 | 1.64% Avg Daily Range (30 D): $0.75 | 1.40% Avg Daily Range (90 D): $0.76 | 1.37% Institutional Daily Volume Avg Daily Volume: 1.21M Avg Daily Volume (30 D): 2.28M Avg Daily Volume (90 D): 1.98M Trade Size Avg Trade Size (Sh.): 103 Avg Trade Size (Sh.) (30 D): 58 Avg Trade Size (Sh.) (90 D): 56 Institutional Trades Total Inst.Trades: 24,022 Avg Inst. Trade: $3.59M Avg Inst. Trade (30 D): $7.08M Avg Inst. Trade (90 D): $5.67M Avg Inst. Trade Volume: .06M Avg Inst. Trades (Per Day): 5 Market Closing Trades Avg Closing Trade: $11.04M Avg Closing Trade (30 D): $37.36M Avg Closing Trade (90 D): $25.17M Avg Closing Volume: 139.92K     News Nov 3, 2025 @ 6:00 PM Pulmonary Emphysema Market Set to Expand by 2034 w... Source: Delveinsight Oct 7, 2025 @ 3:00 PM AAV Gene Therapy Market Size to Skyrocket at 40.1%... Source: Towards Healthcare Oct 1, 2025 @ 9:48 AM Pompe Disease Market Analysis Report 2025-2035: En... Source: Researchandmarkets.Com Aug 19, 2025 @ 4:08 AM Predicting the Next Rule Breaker Buyout Source: Rick Munarriz Aug 5, 2025 @ 5:11 PM BioMarin Discontinues Preclinical Drug Candidate, ... Source: Vandana Singh Financials   TTM Q3 2025 Q2 2025 Basic EPS $2.73 $-.16 $1.25 Diluted EPS $2.68 $-.16 $1.23 Revenue $ 3.09B $ 776.13M $ 825.41M Gross Profit $ 2.52B $ 636.05M $ 675.32M Net Income / Loss $ 520.42M $ -30.74M $ 240.53M Operating Income / Loss $ 615.5M $ -46.69M $ 276.89M Cost of Revenue $ 577.87M $ 140.09M $ 150.09M Net Cash Flow $ 575.9M $ 35.55M $ 168.08M PE Ratio 19.72